PDS Biotech reports mOS 39.3 months in VERSATILE-002 Phase 2 vs 17.9 months standard of care

PDS Biotechnology Corp

Median overall survival of 39.3 months (lower bound 23.9) in CPS≥1 patients with HPV16+ HNSCC; standard pembrolizumab ± chemo mOS is 17.9 months.
53 patients enrolled; no discontinuations due to treatment-related adverse events.
Phase 3 VERSATILE-003 trial is underway based on these results.
Durable multifunctional HPV16-specific CD8+ T cells induced by PDS0101 observed across demographics.
Full data set to be published later this year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.